Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Overview of a Daiichi Sankyo-sponsored clinical trial examining patterns of care and outcomes in locally recurrent inoperable or metastatic …
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy [Phase 1]
Phase 1 study of ITC-6146RO in patients with advanced or metastatic cancers after standard therapy; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC [Phase 2]
A Phase 2 clinical trial from the University of Utah uses functional precision oncology to predict, prevent, and treat early metastatic recu…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors [EARLY_Phase 1]
Early-phase clinical trial investigating a radiolabeled anti-PD-L1 single-domain antibody (177Lu-anti-PD-L1 sdAb) in metastatic solid tumors…
-
CLINICAL_TRIALS other · 2026-02-19Clinical Trial Update: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) [NA]
The MAGENTA clinical trial (NCT02993068) sponsored by MD Anderson Cancer Center is suspended; it investigates hereditary gene mutations and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating re-challenge immunotherapy with cromolyn, TQB2102, and panpulimab in immune-refractory triple-negat…
-
CLINICAL_TRIALS withdrawal · 2026-02-19Clinical Trial Update: A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) [Phase 2]
The Phase 2 trial MK-5890-003 evaluating boserolimab with pembrolizumab and chemotherapy for early triple-negative breast cancer has been wi…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating nab-paclitaxel plus atezolizumab given before surgery in triple-negative breast cancer has completed and posted res…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial assessing whether combining propranolol with pembrolizumab can re-sensitize checkpoint inhibitor-refractory metastati…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: NearWave Optical Molecular Monitoring [NA]
A recruiting clinical trial from Indiana University evaluating NearWave Optical Molecular Monitoring for breast cancer, including HER2-posit…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Saci Nivo Rela for TNBC [Phase 1, Phase 2]
A Yale University-sponsored Phase 1/2 clinical trial evaluating Sacituzumab govitecan in combination with nivolumab and relatlimab for metas…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) [Phase 2]
Phase 2 clinical trial update evaluating the combination of iparomlimab and tuvonralimab (QL1706) with platinum chemotherapy versus platinum…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating radiation therapy combined with pembrolizumab and olaparib (or other radiosensitizers) in women with …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer [Phase 2]
This clinical trial update describes a Phase 2 study sponsored by the University of Chicago evaluating chemotherapy in Nigerian women with t…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial at Ohio State Comprehensive Cancer Center is testing a neoadjuvant complete-response–driven, customized tre…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
This ClinicalTrials.gov entry describes a study by A2 Biotherapeutics evaluating HLA LOH analysis and apheresis for CAR-T cell manufacturing…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients [Phase 1]
This entry notes a Phase 1 clinical trial evaluating a cancer immunotherapeutic PCI strategy in patients with triple-negative breast cancer;…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC [EARLY_Phase 1]
An early-phase study is evaluating sequential bortezomib, pembrolizumab, and cisplatin in metastatic triple-negative breast cancer. The tria…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Adjuvant Intensification for LAR [Phase 3]
A Phase 3 clinical trial evaluating adjuvant intensification for LAR in breast cancer, including triple-negative breast cancer. The study st…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial [Phase 2]
MD Anderson Cancer Center is conducting a Phase 2 trial (MolecularPCR) to optimize adjunct systemic therapy in early-stage HER2-positive and…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) [Phase 1, Phase 2]
Clinical trial update for MR001 in locally recurrent or metastatic advanced triple-negative breast cancer. The study is a Phase 1/Phase 2 tr…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating dendritic cell vaccines targeting Her2/Her3 in combination with pembrolizumab for brain metastases arisi…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors [Phase 1]
Phase 1 study update for NRM-823 in locally advanced or metastatic refractory solid tumors, currently recruiting. The trial lists head and n…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
This clinical trial update shows that recruitment is ongoing for a study examining immunotherapy-related CRP kinetics in patients with early…